Navigation Links
Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
Date:10/18/2011

RICHMOND, Calif., Oct. 18, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its third quarter 2011 financial results on Tuesday, October 25, 2011, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.

The conference call dial-in numbers are 877-377-7553 for domestic callers and 678-894-3968 for international callers. The passcode for the call is 20389876.  Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under "Events and Presentations" http://investor.sangamo.com/events.cfm. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on October 25, 2011 to midnight ET on November 1, 2011. The conference call replay numbers for domestic and international callers are 855-859-2056 and 404-537-3406 respectively. The conference ID number for the replay is 20389876.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of ZFP Therapeutics®, novel DNA-binding proteins for therapeutic gene regulation and modification. Sangamo has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins called zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
2. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
3. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
4. Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology
5. Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast
6. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
7. Sangamo Announces Pricing of Public Offering of Common Stock
8. Sangamo Announces Public Offering of Common Stock
9. Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntingtons Disease
10. Sangamo BioSciences Announces Presentation at the 10th Annual Needham Healthcare Conference
11. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... ... of life, today announced its full advisory board. The board comprises leaders spanning ... of James Crooks, PhD, former VP of Engineering, to Chief Technology Officer. Crooks ...
(Date:7/20/2017)... DENVER and PLYMOUTH, Minn., July 20, 2017 ... LLC , a personalized genetic evaluations company, today ... under their partnership investigating a genetic mutation implicated ... to extend the partnership for a second case ... Last year, the KCNQ2 Cure Alliance and Pairnomix ...
(Date:7/18/2017)... ... July 18, 2017 , ... Nanomedical Diagnostics, a cutting-edge ... the launch of a new NTA biosensor chip for use with its label-free ... kinetics of polyhistidine-tagged (His-tagged) molecules quickly and reliably. , “Recombinant proteins are ...
(Date:7/18/2017)... ... ... G-CON today announced that it has received Notices of ... 14/858,857 and 13/669,785 both entitled Modular, Self-Contained, Mobile Clean Room. The U.S. Patent ... G-CON’s R&D investments and validate the G-CON platform as a novel way to ...
Breaking Biology Technology:
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:3/30/2017)... HONG KONG , March 30, 2017 ... developed a system for three-dimensional (3D) fingerprint identification by adopting ground ... technology into a new realm of speed and accuracy for use ... applications at an affordable cost. ... ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
Breaking Biology News(10 mins):